GenAI in the Life Sciences SDLC: Realms & Realities
Life sciences companies are under increasing pressure to innovate faster while navigating some of the most complex operating environments in the world. Software systems must manage sensitive patient data, adhere to evolving regulatory frameworks and support mission-critical activities like clinical trials, medical device development, pharmacovigilance and laboratory operations — all without compromising compliance or quality.
Yet the software development life cycle (SDLC) in life sciences is notoriously slow and expensive. Requirements are dense and ever-changing, testing is exhaustive, documentation demands are overwhelming and validation delays can stretch timelines by months. Enter Generative AI (GenAI).
GenAI is beginning to make a tangible impact in the SDLC for life sciences organizations. We’ll spotlight the biggest areas of opportunity, but ground each one in reality — exploring how it’s working in practice today and what barriers remain.
- Tackling Regulatory Complexity at the Requirements Stage
The Challenge: Life sciences teams spend a significant amount of time translating complex regulatory frameworks (FDA 21 CFR Part 11, good practice guidelines (GxP), GDPR, HIPAA) into software requirements. Even minor misinterpretations can lead to costly rework or failed audits.
Why GenAI: GenAI can rapidly analyze regulatory documents, clinical protocols and industry guidelines, then draft clear, structured requirement sets. It can flag potential compliance gaps before development begins. This reduces ambiguity, accelerates the design phase and helps ensure solutions are “compliant by design” rather than retrofitted for validation later.
Reality Check: While this works well in controlled pilots, success hinges on high‑quality input data and domain-specific fine-tuning. If the AI is trained on incomplete or outdated regulatory content, it can generate misleading or overly generic outputs. There’s also a risk of “false confidence” — teams may assume the AI caught every nuance, only to discover gaps later in audits (though we’ve seen applications of agentic AI as “auditor” begin to safeguard against these gaps). So far, most organizations have used GenAI as a starting point, not a replacement for human regulatory expertise. - Breaking Down Silos & Accelerating Coding
The Challenge: Life sciences organizations often work with fragmented systems — clinical trial management platforms, lab information systems, enterprise resource planning (ERP) tools and regulatory submission portals that rarely talk to one another. Developers must spend extra effort integrating legacy systems while maintaining validated environments.
Why GenAI: AI-powered code assistants speed up development by suggesting context-specific code, generating API integrations and even refactoring legacy code for better performance and maintainability. In highly regulated settings, GenAI can incorporate industry best practices to align with validation and security requirements.
Reality Check: Coding assistance has been one of the more successful GenAI applications, but integration challenges remain. Legacy systems in life sciences are often customized and poorly documented, making AI-generated code difficult to validate or deploy without human review. There’s also a risk of “black box” outputs — teams don’t always understand why the AI made a specific coding suggestion, which can be problematic for auditability. In practice, GenAI has boosted productivity for routine coding tasks, but mission-critical, validated code still requires full oversight. - Automating Testing in a High-Stakes Environment
The Challenge: Testing in life sciences isn’t just about functionality — it’s about ensuring every feature aligns with safety and regulatory expectations. User acceptance testing (UAT), validation protocols and audit trails consume a disproportionate amount of time and resources.
Why GenAI: GenAI can generate comprehensive test scripts (and even test data), simulate real-world lab or clinical scenarios and ensure traceability between requirements and test results. It can highlight gaps in testing and validation coverage — critical in preparing for FDA or EMA inspections. This reduces the risk of non-compliance while speeding up testing cycles.
Reality Check: Automating test generation works well for functional testing but is less effective for nuanced validation scenarios where patient safety or regulatory compliance is at stake. AI-generated test cases often need extensive review to ensure they align with GxP standards. The bigger risk here is over-reliance: if teams skip manual validation of AI-generated tests, they may miss subtle edge cases that regulators would flag. - Streamlining Validation and Documentation
The Challenge: Documentation is both the lifeblood and bottleneck of life sciences SDLC. Every change requires updated traceability matrices, validation reports and standard operating procedures (SOPs). Manual documentation not only slows progress but also increases the risk of errors.
Why GenAI: GenAI can auto-generate and maintain compliance-ready documentation — from validation protocols to audit-ready change logs — saving countless hours of manual work. By integrating with existing quality management systems, it helps documents stay synchronized with the actual system state, making regulatory audits far less painful.
Reality Check: Documentation automation shows promise but has struggled with contextual accuracy, for example, ensuring the right level of detail for specific regulatory bodies or matching the exact formatting and style expected in submissions. The risk here is “automation complacency” — if teams trust AI-generated documentation without verification, they could face noncompliance in audits. - Balancing Innovation with Oversight
The Challenge: Life sciences companies can’t afford to move fast and break things. They must innovate responsibly while protecting patient data, maintaining auditability and ensuring ethical AI use. Many struggle with governance models that allow GenAI adoption without introducing risk.
Why GenAI: While GenAI doesn’t replace the need for strong governance, it can assist with policy enforcement. For example, it can flag potential data privacy violations, help generate risk assessments and provide explainable outputs for auditability. When combined with a clear oversight framework, GenAI becomes an enabler of responsible innovation rather than a risk factor.
Reality Check: This remains one of the hardest areas to get right. AI governance in life sciences is still immature — many companies lack clear policies on model training data, auditability and explainability. The main risks are data leakage (using sensitive patient data to train models) and regulatory uncertainty (AI-generated outputs may raise questions about authorship and responsibility).
Generative AI is a powerful accelerant for the SDLC in all industries, but those in life sciences have much to gain from its integration. When paired with appropriate governance and human supervision, and fine-tuned to domain specifications, it can streamline some of the most time-consuming, resource-heavy stages of development.
As always, the real opportunity lies in striking the right balance between innovation and compliance — and finding the right partners to help you do so. Learn more about EPAM’s work in Life Sciences and Healthcare, AI and the SDLC.
